• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    GW Pharmaceuticals plc (GWPH)

    -NasdaqGM
    68.09 Down 1.99(2.84%) 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    GW Pharmaceuticals plc
    Porton Down Science Park
    Salisbury, SP4 0JQ
    United Kingdom - Map
    Phone: 44 19 8055 7000
    Fax: 44 19 8055 7111
    Website: http://www.gwpharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:265

    Business Summary 

    GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on GW Pharmaceuticals plc

    Key Executives 
     PayExercised
    Dr. Geoffrey W. Guy BSc, MB BS, MRCS Eng, LRCP, LMSSA. Dip Pharm Med, 59
    Founder, Exec. Chairman and Chairman of Nominations Committee
    N/AN/A
    Mr. Justin D. Gover BSc,MBA, 43
    Chief Exec. Officer, Managing Director and Exec. Director
    N/AN/A
    Mr. Adam David George BSc, ACA, 44
    Chief Financial Officer, Company Sec. and Exec. Director
    N/AN/A
    Mr. Christopher John Tovey BSc, 48
    Chief Operating Officer and Exec. Director
    N/AN/A
    Dr. Stephen Wright MA, M.D., FRCP (Edin), FFPM., 62
    R&D Director and Exec. Director
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.